Core Insights - The company reported a revenue of 12.386 billion, a year-on-year decline of 20.72%, and a net profit attributable to shareholders of 0.027 billion, down 96.76% year-on-year [1] - The company is facing short-term performance pressure due to high inventory levels and a high base from 2023, leading to a significant drop in sales across various therapeutic areas [2] - The company is undergoing marketing transformation aimed at revitalizing its brand and improving sales performance through innovative marketing strategies and organizational restructuring [3] - The company is projected to experience revenue growth in the coming years, with expected revenues of 13.663 billion, 15.047 billion, and 16.627 billion for 2025-2027, reflecting a compound annual growth rate of approximately 10% [4] Financial Performance - In 2024, the company achieved a revenue of 12.386 billion, a decrease of 20.72% year-on-year; net profit attributable to shareholders was 0.027 billion, down 96.76% year-on-year; and non-recurring net profit was 0.039 billion, down 95.02% year-on-year [1] - In Q4 alone, the company reported a revenue of 1.952 billion, a decline of 43.25% year-on-year, with a net loss of 0.518 billion, marking a shift from profit to loss [1] Sales Performance by Therapeutic Area - The pharmaceutical segment generated sales of 7.038 billion, a year-on-year decrease of 32.25%, with notable declines in various therapeutic areas: - Respiratory medications: 2.164 billion, down 18.11% - Digestive and metabolic medications: 1.873 billion, down 35% - Anti-infective drugs: 0.964 billion, down 48.43% - Neurological medications: 0.614 billion, down 31.65% - Health products: 0.605 billion, down 28.77% - Cardiovascular medications: 0.505 billion, down 34.12% - Anti-tumor and immune-regulating drugs: 0.205 billion, down 16.49% [2] Marketing and Organizational Changes - The company is implementing a marketing transformation that includes youth-oriented branding and cross-industry promotions, such as featuring its products at London Fashion Week [3] - The organizational structure has been revised, with the establishment of a market center and sales center, and a reduction of functional departments to 16, aimed at enhancing management efficiency and employee engagement [3] Future Projections - Revenue projections for 2025-2027 are as follows: - 2025: 13.663 billion, growth of 10.31% - 2026: 15.047 billion, growth of 10.13% - 2027: 16.627 billion, growth of 10.50% - Net profit projections for the same period are: - 2025: 0.597 billion, growth of 2138.21% - 2026: 0.732 billion, growth of 22.76% - 2027: 0.861 billion, growth of 17.55% - Earnings per share (EPS) are expected to be 1.07, 1.32, and 1.55 for 2025, 2026, and 2027 respectively [4]

Overview - The women's health supplement market in China is projected to reach a market size of 268.28 billion yuan in 2024, driven by increased health awareness and disposable income among women [1][10] - The market is segmented into various categories, with nutritional supplements accounting for approximately 30.5%, beauty and skincare products for 22.2%, and weight loss supplements for 21.2% [1][10] Market Policies - Recent policies such as the "Quality Strong Country Construction Outline" and "Measures to Restore and Expand Consumption" have been implemented to improve market order and support the women's health supplement industry [3][4] Industry Chain - The upstream of the women's health supplement industry includes suppliers of raw materials like herbal medicine, biological agents, and plant extracts, which significantly impact production costs [6] - The downstream consists of various sales channels including pharmacies, supermarkets, specialty stores, and e-commerce platforms [6] Consumer Demographics - In 2024, the female population in China is estimated to be 689.19 million, representing 48.94% of the total population, providing a solid consumer base for the women's health supplement industry [8] Competitive Landscape - The industry features numerous participants, including domestic companies like汤臣倍健 (Tongrentang) and东阿阿胶 (Dong'e Ejiao), as well as international brands like Swisse and Amway [12][14] - Tongrentang has established itself as a leader with a diverse product line and strong nutritional research capabilities, while Dong'e Ejiao focuses on traditional products catering to specific demographic needs [12][14][16] Industry Trends - Future demand for women's health supplements is expected to shift from single-function products to multi-dimensional solutions, focusing on immune support, weight management, and beauty [18] - There is a growing preference for natural ingredients and products that combine traditional Chinese health elements with modern formulations [18]

风险提示：集采降价风险，渠道拓展不及预期风险。 2024 年公司研发费用2.8 亿元（+19.7%）。全年在研项目61 项，一致性评价17 项；7个品种10 个规格 通过一致性评价，取得药品注册标准10 件，盐酸羟考酮缓释片获得生产批件，获专利授权48 项。 盈利预测与投资建议：考虑到公司主业产品恢复增长。预计2025-2027 年归母利润分别5.9 亿元、7.8 亿 元和8.9 亿元，对应PE 为21 倍、16 倍和14 倍，建议保持关注。 事件：公司发布2024年年报，2024年实现营收123.9亿元（-20.7%），归母净利润为0.3 亿元 （-96.8%），扣非归母净利润0.4 亿元（-95.0%），经营性现金流量净额-6.3 亿元（-194.0%）。 多因素叠加致公司业绩承压，大健康板块表现亮眼。2024 年公司营收123.9 亿元（-20.7%），主要系高 基数、高社会库存影响。分板块看：1）医药工业营收70.4 亿元（-32.3%）。从细分领域看，消化代谢 用药/呼吸系统用药/抗感染药物/ 神经系统用药分别实现营收18.7/21.6/9.6/6.1 亿元， 同 比-35.0%/-18.1%/-4 ...

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]

文｜白马商评 崩了！市值百亿的中药头部公司太极集团也扛不住了。 | 序号 | 证券代码 | 让券商称 | 营业总收入(同比增长率) | 归属母公司股东的净利润(同比增长率) | | 扣除非经 | | --- | --- | --- | --- | --- | --- | --- | | | | | [报告期] 2024年报 | [报告期] 2024年报 | | 【报告期】 | | | | | [单位] %1 | [单位] % | | [单位] % | | 1 | 600252.SH | 中恒集团 | -26.6658 | | -547.1410 | | | 2 | 600129.SH | 太极集团 | -20.7176 | | -96.7581 | | | 3 | 000989.SZ | ST九芝 | -19.9136 | | -27.3053 | | | 4 | 600976.SH | 健民集团 | -16.8085 | | -30.5450 | | | 5 | 000590.SZ | 启迪药业 | -15.1835 | | -596.9803 | | | 6 | 300534.SZ | 陇神戎发 | -3 ...

●重庆太极实业（集团）股份有限公司(以下简称：公司)2024 年度不进行利润分配，即不派发现金红利，不送股和资本公积金转增 股本。 ●本次利润分配已经公司第十届董事会第二十七次会议、第十届监 事会第二十二次会议审议通过，尚需提交公司 2024 年年度股东会审议。 证券代码：600129 证券简称：太极集团 公告编号：2025-021 重庆太极实业（集团）股份有限公司 关于公司 2024 年度拟不进行利润分配的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》 （以下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的 可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 公司经天健会计师事务所（特殊普通合伙）2024 年度财务审计， 2024 年度归属于上市公司股东的净利润为 2,665.27 万元，提取法定 盈余公积金 4,322.96 万元，加上年初未分配利润 88,690.22 万元， 减 ...

重庆太极实业（集团）股份有限公司 2024 年度独立董事述职报告 作为重庆太极实业（集团）股份有限公司(以下简称:公司)的独 立董事，本人严格按照《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》《上海证券交易所股票上市规则》等相关 法律法规的规定，以及《公司章程》和公司《独立董事工作制度》的 要求，勤勉尽责，认真审慎地履行了独立董事职责，积极主动了解公 司的生产经营和运行情况，按时出席相关会议，对公司董事会审议的 重大事项充分发挥自身的专业优势发表独立董事意见，并提出自己的 意见和建议，切实维护公司整体利益特别是中小股东的合法权益。现 将本人2024年度履职情况汇报如下： 一、独立董事情况 （一）独立董事基本情况 熊少希，男，1956 年出生，中共党员，湖南中医药大学中药专 业硕士研究生，执业药师、教授级高级工程师。历任湖南中医学院助 理研究员，佛山制药厂总经理助理、技术厂长，美国雅莱制药（佛山） 康宝顺药业有限公司副总裁、高级副总裁，香港宏安集团湘雅制药公 司总经理，广州美晨药业公司常务副总经理，广东环球制药有限公司 总经理，盈天医药集团有限公司副总经理兼生产中心总监，中国中药 控股有 ...

Financial Performance - The company's net profit attributable to shareholders for 2024 is CNY 26,652,727.94, a decrease of 96.76% compared to CNY 822,124,918.06 in 2023[8]. - Total revenue for 2024 is CNY 12,386,016,983.42, reflecting a decline of 20.72% from CNY 15,622,648,416.93 in 2023[26]. - The net cash flow from operating activities for 2024 is CNY -631,462,933.69, a significant drop from CNY 671,536,615.17 in 2023, representing a change of -194.03%[26]. - The company's total assets decreased by 2.46% to CNY 14,057,759,232.64 at the end of 2024, down from CNY 14,411,774,083.52 at the end of 2023[26]. - The net assets attributable to shareholders decreased by 3.59% to CNY 3,492,167,957.47 at the end of 2024, compared to CNY 3,622,185,106.00 at the end of 2023[26]. - The company reported a net profit excluding non-recurring gains and losses of CNY 38,539,284.46 for 2024, down 95.02% from CNY 774,448,432.63 in 2023[26]. - The company will not distribute profits for 2024, citing significant future operational funding needs[8]. Sales and Revenue Breakdown - The company achieved a revenue of 12.386 billion RMB in 2024, a decrease of 20.72% year-on-year[37]. - The pharmaceutical manufacturing segment reported sales of 7.038 billion RMB, a decline of 32.25% year-on-year[37]. - The pharmaceutical commerce segment generated sales of 6.740 billion RMB, down 9.00% year-on-year[37]. - The traditional Chinese medicine resources segment saw sales of 1.053 billion RMB, an increase of 0.82% year-on-year[37]. - The health and international business segment achieved sales of 461 million RMB, a growth of 39.43% year-on-year[37]. Research and Development - The company has 61 ongoing research projects, including 19 in traditional Chinese medicine and 18 in chemical medicine[38]. - The company obtained 10 drug registration standards and 48 patent authorizations during the reporting period[38]. - The company recruited 2 PhDs and 31 Masters to enhance its research talent pool[39]. - The company established two major innovation centers in Fuling and Chongqing to improve its research capabilities[39]. - The company successfully integrated 13 products into 10 treatment guidelines, 19 expert consensus documents, and 11 treatment/prevention plans during the reporting period[40]. - The company’s R&D expenses increased by 19.67% to 279.57 million RMB, reflecting a commitment to innovation[70]. - The company is focusing on R&D and innovation to adapt to the evolving regulatory landscape in the pharmaceutical industry[90]. Market and Product Development - The company is strategically expanding its import and export business, with significant new market entries in regions such as Singapore, Indonesia, and the UAE[47]. - The company is actively restructuring its marketing organization to enhance management efficiency and has streamlined its functional departments to 16[49]. - The company’s marketing strategy includes cross-industry promotions and collaborations to enhance brand visibility among younger consumers[42]. - The company aims to enhance its core competitiveness through innovative drug development, focusing on 12 major diseases and leveraging modern technology[58]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio and market share in the healthcare industry[93]. Operational Efficiency and Cost Management - The company’s production capacity construction includes the establishment of a "Lighthouse Factory" at the Fuling Pharmaceutical Plant, enhancing manufacturing capabilities[43]. - The company’s comprehensive energy consumption per 10,000 yuan of output value was 0.0582 tons of standard coal, which is 2.7% lower than the target value[43]. - The company has a centralized procurement model that enhances efficiency and reduces costs, implementing strict quality control measures and supplier management to optimize the supply chain[56]. - The company plans to enhance product quality and reduce production costs in response to the competitive pricing pressures from national drug procurement policies[91]. - The company is focusing on establishing stable relationships with quality suppliers to control raw material costs effectively[137]. Governance and Shareholder Relations - The company has established a three-year shareholder return plan for 2024-2026 to enhance investor trust and protect their rights[144]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[144]. - The company emphasizes investor relations management, maintaining close communication with investors through various channels[143]. - The board of directors held eight meetings, with independent directors providing valuable insights for the company's long-term development[142]. - The company has organized two shareholder meetings in the reporting period, ensuring equal voting rights and transparency in decision-making[141]. Environmental and Social Responsibility - Environmental protection investments during the reporting period totaled CNY 10.86 million[192]. - The company operates wastewater treatment facilities with a daily capacity of 450 tons and 300 tons for its subsidiaries, ensuring compliance with relevant discharge standards[196][197]. - Emergency response plans for environmental incidents have been developed and filed by both Southwest Pharmaceutical and Zhejiang Oriental[199]. - The company has established an internal control system focusing on compliance management and risk prevention, enhancing operational management levels[188]. Future Outlook - The company provided a positive outlook for 2024, projecting a revenue growth of 10-12%[151]. - The company aims to achieve a revenue growth target of 10% for the upcoming fiscal year[149]. - The company plans to invest in new technologies to improve operational efficiency and product quality[149]. - The company is committed to maintaining transparency and accountability in its financial reporting practices[149].

二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 24839.28万股，累计占流通股比： 44.61%，较上期变化： -891.08万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 太极集团（600129）有限公司 | 15381.24 | 27.62 | 不变 | | 重庆市涪陵页岩气产业投资发展有限公司 | 4409.53 | 7.92 | 不变 | | 重庆市涪陵区希兰生物科技有限公司 | 1189.53 | 2.14 | 不变 | | 富国研究精选灵活配置混合A | 588.54 | 1.06 | 新进 | | 重庆市涪陵实业发展集团有限公司 | 585.68 | 1.05 | 不变 | | 香港中央结算有限公司 | 561.36 | 1.01 | -531.47 | | 南方中证500ETF | 556.67 | 1.00 | -82.13 | | 富国天惠成长混合(LOF) | 540.77 | 0.97 | 新进 | | 中国人寿（601628）保险股份有限公司-传 ...

凤凰网《风暴眼》出品 文｜玲子 2024 年底，北方一家制药公司的办公室里，几位研发、采购人员围坐一圈，在稿纸上、白板上疾笔写下一串串数字。 3 分钱 / 片的阿司匹林肠溶 片、 0.22 元 / 支的间苯三酚注射液，按照理论成本，无论换多少种计算方法，他们也算不出这个价格。此时，第十批集采的中标价刚刚出炉，整个 医药圈都骚动起来。 "至少需要五六毛！"有人把笔一搁，最后一轮演算，成本价最多还是只能压到这里。研发主管郭青沉思片刻，试图给出合理解释："估计是为了打出 品牌"。马上有人附和："如果企业技术很厉害，应该有更好的方式控制成本吧……" 郭青在仿制药研发领域摸爬滚打了七年，经手过 50 余个研发项目。他所在的公司曾参与集采竞标，有几款产品顺利中标。通常，他会遇到两三毛钱 的压价，觉得这在预期范围之内，规模效应带来的持续订单和利润，与暂时的让价相比，总是更有诱惑力的。但第十批集采的激烈厮杀，他却前所未 见。 而近期，就在第十批集采落地前夕，饱受争议的超低价中标药间苯三酚注射液忽然被曝出不符合要求，两家涉事药企遭同步重罚 —— 委托方四川海 梦智森生物制药有限公司（下称"海梦智森"）与受托方太极集团四川太极制 ...